MOLECULE: ABP 798
CLINICAL TRIALS:
Study title Phase Status
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabPhase 3Active, not recruiting

Developed in collaboration with Allergan, ABP 798 has not been approved. The potential approved indications may differ from the reference product primary indications, which may differ depending on jurisdictions.